Search Results

There are 2060 results for: content related to: ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

  1. You have free access to this content
    Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

    Cancer

    Volume 121, Issue 1, January 1, 2015, Pages: 17–24, Amelia B. Zelnak and Kari B. Wisinski

    Article first published online : 23 JUL 2014, DOI: 10.1002/cncr.28815

  2. You have free access to this content
    Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors

    Cytometry Part A

    Volume 79A, Issue 9, September 2011, Pages: 684–693, Simone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, Olaf Ortmann and Gero Brockhoff

    Article first published online : 22 JUL 2011, DOI: 10.1002/cyto.a.21107

  3. Biomarkers of drugs targeting HER-family signalling in cancer

    The Journal of Pathology

    Volume 232, Issue 2, January 2014, Pages: 219–229, Filippo Montemurro and Maurizio Scaltriti

    Article first published online : 10 DEC 2013, DOI: 10.1002/path.4269

  4. Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 1, January 2014, Pages: 60–71, Stephanie J. Malenfant, Karen R. Eckmann and Chad M. Barnett

    Article first published online : 5 AUG 2013, DOI: 10.1002/phar.1338

  5. You have free access to this content
    Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S4, June 2014, Pages: 15–25, Richard De Boer, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence Francis, Michael Green, Ken Pittman, Michelle White, Nicholas Wilcken, Nicholas Zdenkowski and Richard Bell

    Article first published online : 6 MAY 2014, DOI: 10.1111/ajco.12207

  6. You have free access to this content
    Systemic treatment of HER2-positive metastatic breast cancer: A systematic review

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S4, June 2014, Pages: 1–14, Nicholas Wilcken, Nicholas Zdenkowski, Michelle White, Ray Snyder, Ken Pittman, Paul Mainwaring, Michael Green, Prudence Francis, Richard De Boer, Maree Colosimo, Sue Chua, Jacquie Chirgwin, Jane Beith and Richard Bell

    Article first published online : 6 MAY 2014, DOI: 10.1111/ajco.12206

  7. You have full text access to this Open Access content
    Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

    Cancer Science

    Volume 102, Issue 1, January 2011, Pages: 1–8, Toru Mukohara

    Article first published online : 6 SEP 2010, DOI: 10.1111/j.1349-7006.2010.01711.x

  8. You have free access to this content
    Current and emerging targeted therapies for metastatic breast cancer

    Cancer

    Volume 118, Issue 12, 15 June 2012, Pages: 3014–3025, Edith A. Perez and Jean-Philippe Spano

    Article first published online : 17 OCT 2011, DOI: 10.1002/cncr.26356

  9. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

    International Journal of Gynecological Cancer

    Volume 18, Issue 5, September/October 2008, Pages: 879–890, M.J. PALAYEKAR and T.J. HERZOG

    Article first published online : 5 DEC 2007, DOI: 10.1111/j.1525-1438.2007.01144.x

  10. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 3, March 2013, Pages: 794–812, Zephania W. Kwong Glover, Lynn Gennaro, Sandeep Yadav, Barthélemy Demeule, Pin Yee Wong and Alavattam Sreedhara

    Article first published online : 5 DEC 2012, DOI: 10.1002/jps.23403

  11. You have free access to this content
    Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells

    International Journal of Cancer

    Volume 127, Issue 3, 1 August 2010, Pages: 696–706, Jeanett Fischgräbe, Martin Götte, Katharina Michels, Ludwig Kiesel and Pia Wülfing

    Article first published online : 3 DEC 2009, DOI: 10.1002/ijc.25076

  12. Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

    Clinical Pharmacology in Drug Development

    Volume 2, Issue 1, January 2013, Pages: 11–24, Manish Gupta, Bei Wang, Timothy J. Carrothers, Patricia M. LoRusso, Yu-Waye Chu, Ted Shih, David Loecke, Amita Joshi, Ola Saad, Joo-Hee Yi and Sandhya Girish

    Article first published online : 26 FEB 2013, DOI: 10.1002/cpdd.9

  13. You have free access to this content
    Cardiac toxicity in breast cancer patients treated with dual HER2 blockade

    International Journal of Cancer

    Volume 133, Issue 9, November 2013, Pages: 2245–2252, Antonis Valachis, Andreas Nearchou, Nikolaos P. Polyzos and Pehr Lind

    Article first published online : 29 MAY 2013, DOI: 10.1002/ijc.28234

  14. Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?

    Cancer

    Volume 121, Issue 4, February 15, 2015, Pages: 517–526, Elisavet Paplomata, Rita Nahta and Ruth M. O'Regan

    Article first published online : 24 OCT 2014, DOI: 10.1002/cncr.29060

  15. Tyrosine Kinase Inhibitors

    Targeting Protein Kinases for Cancer Therapy

    David J. Matthews, Mary E. Gerritsen, Pages: 435–525, 2010

    Published Online : 11 MAR 2010, DOI: 10.1002/9780470555293.ch8

  16. You have free access to this content
    Systemic cancer therapy: Evolution over the last 60 years

    Cancer

    Volume 113, Issue S7, 1 October 2008, Pages: 1857–1887, Grace K. Dy and Alex A. Adjei

    Article first published online : 17 SEP 2008, DOI: 10.1002/cncr.23651

  17. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer

    International Journal of Cancer

    Volume 135, Issue 7, 01 October 2014, Pages: 1517–1530, Christiane Daniela Fichter, Sylvia Timme, Julia Alexandra Braun, Verena Gudernatsch, Anja Schöpflin, Lioudmilla Bogatyreva, Helene Geddert, Gerhard Faller, David Klimstra, Laura Tang, Dieter Hauschke, Martin Werner and Silke Lassmann

    Article first published online : 2 APR 2014, DOI: 10.1002/ijc.28771

  18. Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue 4, December 2014, Pages: 368–375, Arlene Chan, Catherine Shannon, Richard de Boer, Sally Baron-Hay, Andrew Redfern, Astrid Bauwens, Paul Craft, Suzanne Webb, Amanda Townsend and Dusan Kotasek

    Article first published online : 28 OCT 2014, DOI: 10.1111/ajco.12292

  19. Epidermal growth factor receptor blockers for the treatment of ovarian cancer

    Intervention Review

    The Cochrane Library

    Krishnayan Haldar, Kezia Gaitskell, Andrew Bryant, Shibani Nicum, Sean Kehoe and Jo Morrison

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD007927.pub3

  20. You have full text access to this OnlineOpen article
    ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells

    Cancer Medicine

    Volume 1, Issue 1, August 2012, Pages: 28–38, Byung-Kwon Choi, Xuejun Fan, Hui Deng, Ningyan Zhang and Zhiqiang An

    Article first published online : 15 JUL 2012, DOI: 10.1002/cam4.10